News
These Results Compare Well with 65.2% Efficacy Against Delta Variant Obtained During ... - Latest Tweet by ANI
The latest Tweet by ANI states, 'These results compare well with 65.2% efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among general population. Study also shows,COVAXIN meets WHO efficacy criteria for COVID19 vaccines for dreaded Delta variant:BharatBiotech ...'
These results compare well with 65.2% efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among general population. Study also shows,COVAXIN meets WHO efficacy criteria for COVID19 vaccines for dreaded Delta variant:BharatBiotech https://t.co/sFC21Fw5JO pic.twitter.com/RUjetpJHS5— ANI (@ANI) November 25, 2021
(The above story first appeared on LatestLY on Nov 25, 2021 07:40 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
